Remimazolam for sedation in gastrointestinal endoscopy:A comprehensive review

作     者：Dushyant Singh Dahiya Ganesh Kumar Syeda Parsa Manesh Kumar Gangwani Hassam Ali Amir Humza Sohail Saqr Alsakarneh Umar Hayat Sheza Malik Yash R Shah Bhanu Siva Mohan Pinnam Sahib Singh Islam Mohamed Adishwar Rao Saurabh Chandan Mohammad Al-Haddad 

作者机构：Division of GastroenterologyHepatology&MotilityThe University of Kansas School of MedicineKansas CityMO 66160United States Department of Internal MedicineChandka Medical CollegeSindh 77280Pakistan Department of Gastroenterology and HepatologyUniversity of Arkansas For Medical SciencesLittle RockAR 72205United States Division of GastroenterologyHepatology and NutritionEast Carolina University/Brody School of MedicineGreenvilleNC 27858United States Department of SurgeryUniversity of New Mexico School of MedicineAlbuquerqueNM 87106United States Department of Internal MedicineUniversity of Missouri-Kansas CityKansas CityMO 64108United States Department of Internal MedicineGeisinger Wyoming Valley Medical CenterWilkes BarrePA 18711United States Department of Internal MedicineRochester General HospitalRochesterNY 14621United States Department of Internal MedicineTrinity Health Oakland/Wayne State UniversityPontiacMI 48341United States Department of Internal MedicineJohn H.Stroger Hospital of Cook CountyChicagoIL 60612United States Department of Internal MedicineSinai hospitalBaltimoreMD 21215United States Department of HepatologyUniversity of MissouriColumbiaMO 65211United States Department of Internal MedicineGuthrie Robert Packer HospitalSayrePA 18840United States Division of Gastroenterology and HepatologyCreighton University School of MedicineOmahaNE 68131United States Division of Gastroenterology and HepatologyIndiana University School of MedicineIndianapolisIN 46202United States 

出 版 物：《World Journal of Gastrointestinal Endoscopy》 (世界胃肠内镜杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第7期

页      面：385-395页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Remimazolam Endoscopy Sedation Outcomes Efficacy Safety Pharmacokinetics 

摘      要：Worldwide,a majority of routine endoscopic procedures are performed under some form of sedation to maximize patient ***,benzodiazepines and opioids continue to be widely ***,in recent years,Remimazolam is gaining immense popularity for procedural sedation in gastrointestinal(GI)*** is an ultra-short-acting benzodiazepine sedative which was approved by the Food and Drug Administration in July 2020 for use in procedural *** has shown a favorable pharmacokinetic and pharmacodynamic profile in terms of its non-specific metabolism by tissue esterase,volume of distribution,total body clearance,and negligible drug-drug *** also has satisfactory efficacy and has achieved high rates of successful sedation in GI ***,studies have demonstrated that the efficacy of Remimazolam is non-inferior to Propofol,which is currently a gold standard for procedural sedation in most parts of the ***,the use of Propofol is associated with hemodynamic instability and respiratory *** contrast,Remimazolam has lower incidence of these adverse effects intra-procedurally and hence,may provide a safer alternative to Propofol in procedural *** this comprehensive narrative review,highlight the pharmacologic characteristics,efficacy,and safety of Remimazolam for procedural *** also discuss the potential of Remimazolam as a suitable alternative and how it can shape the future of procedural sedation in gastroenterology.